Publikationen von Priv.-Doz. Dr. Dr. H. Gerullis

Originalarbeiten in Peer reviewed Journals

53. Gleichenhagen J, Arndt C, Casjens S, Töpfer C, Gerullis H, Raiko I, Taeger D, Ecke T, Brüning T, Johnen G. Exploring solid-phase proximity ligation assay for survivin detection in urine. PLoS One. 2022 Jun 29;17(6):e0270535.

52. Kopp D, Kopp J, Bernhardt E, Manka L, Beck A, Gerullis H, Karakiewicz PI, Salomon G, Wiggermann P, Hammerer P, Schiffmann J. 8Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography-Based Primary Staging and Histological Correlation after Extended Pelvic Lymph Node Dissection in Intermediate-Risk Prostate Cancer. Urol Int. 2022;106(1):56-62.

51. Kopp D, Kopp J, Bernhardt E, Manka L, Beck A, Gerullis H, Karakiewicz P, Salomon G, Wiggermann P, Hammerer P, Schiffmann J. 68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography-Based Primary Staging and Histological Correlation after Extended Pelvic Lymph Node Dissection in Intermediate-Risk Prostate Cancer. Urol Int. 2021 May 7;1-7.

50. Steinwender T, Manka L, Grindei M, Tian Z, Winter A, Gerullis H, Karakiewicz PI, Hammerer P, Schiffmann J. Elastography Targeted Prostate Biopsy in Patients under Active Surveillance. Urol Int. 2020;104(11-12):948-953.

49. Kopp J, Kopp D, Bernhardt E, Manka L, Beck A, Gerullis H, Karakiewicz P, Schoerner W, Hammerer P, Schiffmann J. 68Ga-PSMA PET/CT based primary staging and histological correlation after extended pelvic lymph node dissection at radical prostatectomy. World J Urol. 2020 Dec;38(12):3085-3090.

48. Barski D, Gerullis H, Ecke T, Boros M, Brune J, Beutner U, Tsaur I, Ramon A, Otto T. Application of Dried Human Amnion Graft to Improve Post-Prostatectomy Incontinence and Potency: A Randomized Exploration Study Protocol. Adv Ther. 2020 Jan;37(1):592-602.

47. Kokov D, Manka L, Beck A, Winter A, Gerullis H, Karakiewicz PI, Hammerer P, Schiffmann J. Only Size Matters in Stone Patients: Computed Tomography Controlled Stone-Free Rates after Mini-Percutaneous Nephrolithotomy. Urol Int. 2019;103(2):166-171.

46. Geißen W, Engels S, Aust P, Schiffmann J, Gerullis H, Wawroschek F, Winter A. Diagnostic Accuracy of Magnetometer-Guided Sentinel Lymphadenectomy After Intraprostatic Injection of Superparamagnetic Iron Oxide Nanoparticles in Intermediate- and High-Risk Prostate Cancer Using the Magnetic Activity of Sentinel Nodes. Front Pharmacol. 2019 Oct 11;10:1123.

45. Niegisch G, Gerullis H, Lin SW, Pavlova J, Gondos A, Rudolph A, Haas G, Hennies N, Kramer MW. A Real-World Data Study to Evaluate Treatment Patterns, Clinical Characteristics and Survival Outcomes for First- and Second-Line Treatment in Locally Advanced and Metastatic Urothelial Cancer Patients in Germany. J Cancer. 2018 Mar 29;9(8):1337-1348.

44. Ecke TH, Weiß S, Stephan C, Hallmann S, Arndt C, Barski D, Otto T, Gerullis H. UBC® Rapid Test-A Urinary Point-of-Care (POC) Assay for
Diagnosis of Bladder Cancer with a focus on Non-Muscle Invasive High-Grade Tumors: Results of a Multicenter-Study. Int J Mol Sci. 2018 Dec
2;19(12):3841.

43. Winter A, Kowald T, Paulo TS, Goos P, Engels S, Gerullis H, Schiffmann J, Chavan A, Wawroschek F. Magnetic resonance sentinel lymph node
imaging and magnetometer-guided intraoperative detection in prostate cancer using superparamagnetic iron oxide nanoparticles. Int J
Nanomedicine. 2018 Oct 23;13:6689-6698.

42. Winter A, Engels S, Goos P, Süykers MC, Henke RP, Gerullis H, Wawroschek F. Detection of CK19 mRNA Using One-step Nucleic Acid Amplification (OSNA) in Prostate Cancer: Preliminary Results. J Cancer. 2018 Nov 24;9(24):4611-4617.

41. Gleichenhagen J, Arndt C, Casjens S, Meinig C, Gerullis H, Raiko I, Brüning T, Ecke T, Johnen G. Evaluation of a New Survivin ELISA and UBC® Rapid for the Detection of Bladder Cancer in Urine. Int J Mol Sci. 2018 Jan 11;19(1).

40. Winter A, Engels S, Reinhardt L, Wasylow C, Gerullis H, Wawroschek F. Magnetic Marking and Intraoperative Detection of Primary Draining Lymph Nodes in High-Risk Prostate Cancer Using Superparamagnetic Iron Oxide Nanoparticles: Additional Diagnostic Value. Molecules. 2017 Dec 9;22(12).

39. Selinski S, Blaszkewicz M, Ickstadt K, Gerullis H, Otto T, Roth E, Volkert F, Ovsiannikov D, Moormann O, Banfi G, Nyirady P, Vermeulen SH, Garcia-Closas M, Figueroa JD, Johnson A, Karagas MR, Kogevinas M, Malats N, Schwenn M, Silverman DT, Koutros S, Rothman N, Kiemeney LA, Hengstler JG, Golka K. Identification and replication of the interplay of four genetic high-risk variants for urinary bladder cancer. Carcinogenesis. 2017 Dec 7;38(12):1167-1179.

38. Winter A, Kneib T, Wasylow C, Reinhardt L, Henke RP, Engels S, Gerullis H, Wawroschek F. Updated Normogram Incorporating Percentage of Positive Cores to Predict Probability of Lymph Node Invasion in Prostate Cancer Patients Undergoing Sentinel Lymph Node Dissection. J Cancer. 2017 Aug 22;8(14):2692-2698

37. Höhne S, Gerullis H, Blaszkewicz M, Selinski S, Hengstler JG, Otto T, Golka K. Nacetyltransferase 1*10 genotype in bladder cancer patients. J Toxicol Environ Health A. 2017;80(7-8):417-422.

36. Barski D, Gerullis H, Ecke T, Yang J, Varga G, Boros M, Pintelon I, Timmermans JP, Otto T. Bladder Reconstruction with Human Amniotic Membrane in a Xenograft Rat Model: A Preclinical Study. Int J Med Sci. 2017 Mar 11;14(4):310-318.

35. Ecke TH, Barski D, Weingart G, Lange C, Hallmann S, Ruttloff J, Wawroschek F, Gerullis H. Presentation of a method at the Exploration Stage according to IDEAL: Percutaneous nephrolithotomy (PCNL) under local infiltrative anesthesia is a feasible and effective method – retrospective analysis of 439 patients. Int J Med Sci. 2017 Feb 25;14(4):302-309.

34. Barski D, Gerullis H, Ecke T, Varga G, Boros M, Pintelon I, Timmermans JP, Otto T. Human Amniotic Membrane Is Not Suitable for the Grafting of Colon Lesions and Prevention of Adhesions in a Xenograft Rat Model. Surg Innov. 2017 Aug;24(4):313-320

33. Ecke TH, Weiß S, Stephan C, Hallmann S, Barski D, Otto T, Gerullis H. UBC Rapid Test for detection of carcinoma in situ for bladder cancer. Tumour Biol. 2017 May;39(5):1010428317701624.

32. Barski D, Gerullis H, Ecke T, Kranz J, Schneidewind L, Leistner N, Queissert F, Mühlstädt S, Grabbert M, Tahbaz R, Pelzer AE, Joukhadar R, Klinge U, Boros M, Bader W, Naumann G, Puppe F, Otto T. Registry of implants for the reconstruction of pelvic floor in males and females: A feasibility case series. Int J Surg. 2017 Jun;42:27-33.

31. Gerullis H, Ecke TH, Barski D, Bantel C, Weyland A, Uphoff J, Jansen T, Wawroschek F, Winter A. Retrospective analysisof a surgical innovation using the IDEAL framework: radical cystectomy with epidural anesthesia. J Int Med Res. 2017 Apr;45(2):714-722.

30. Gerullis H, Barski D, Georgas E, Borós M, Ramon A, Ecke TH, Selinski S, Luedders D, Kramer MW, Winter A, Wawroschek F, Otto T. Protocol for a Randomized Phase II Trial for Mesh Optimization by Autologous Plasma Coating in Prolapse Repair: IDEAL Stage 3. Adv Ther. 2017 Apr;34(4):995-1006.

29. Gerullis H, Schwartmann K, Ecke TH, Georgas E, Herberg P, Winter A, Wawroschek F, Barski D, Otto T. Transvesical Suprapubic Externalization of Ureteral Stents – Introduction of a Surgical Method at the Development Stage. Urol Int. 2017;99(1):69-76.

28. Barski D, Arndt C, Gerullis H, Yang J, Boros M, Otto T, Kolberg HC. Transvaginal PVDF-mesh for cystozele repair: A cohort study. Int J Surg. 2017 Mar;39:249-254

27. Ecke TH, Huang-Tiel HJ, Golka K, Selinski S, Geis BC, Koswig S, Bathe K, Hallmann S, Gerullis H. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer. Int J Mol Sci. 2016 Nov 10;17(11). pii: E1879.

26. Barski D, Gerullis H, Ecke T, Varga G, Boros M, Pintelon I, Timmermans JP, Winter A, Bagner JW, Otto T. Repair of a vesico-vaginal fistula with amniotic membrane – Step 1 of the IDEAL rcommendations of surgical innovation. Cent European J Urol. 2015;68(4):459-61.

25. Figueroa JD, Middlebrooks Gerullis H et al. Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. Hum Mol Genet. 2016 Mar 15;25(6):1203-14.

24. Ecke TH, Arndt C, Stephan C, Hallmann S, Lux O, Otto T, Ruttloff J, Gerullis H. Preliminary Results of a Multicentre Study of the UBC Rapid Test for Detection of Urinary Bladder Cancer Anticancer Res. 2015 May;35(5):2651-5.

23. Barski D, Gerullis H, Georgas E, Bär A, Lammers B, Ramon A, Ysebaert D, Klosterhalfen B, Boros M, Otto T. Coating of mesh grafts for prolapse and urinary incontinence repair with autologous plasma: exploration stage of a surgical innovation. Biomed Res Int. 2014;2014:296498

22. Rafnar T, Sulem P, Gerullis H et al. Genome-wide association study yields variants at 20p12.2 that associate with urinary bladder cancer. Hum Mol Genet. 2014 Oct 15;23(20):554557

21. Gerullis H, Georgas E, Borós M, Klosterhalfen B, Eimer C, Arndt C, Otto S, Barski D, Ysebaert D, Ramon A, Otto T. Inflammatory reaction as determinant of foreign body reactions is an early and susceptible event after mesh implantation. Biomed Res Int. 2014;2014:510807

20. Gerullis H, Georgas E, Eimer C, Arndt C, Barski D, Lammers B, Klosterhalfen B, Borós M, Otto T. Coating with autologous plasma improves biocompatibility of mesh grafts in vitro: development stage of a surgical innovation. Biomed Res Int. 2013;2013:536814

19. Gerullis H, Eimer C, Ecke TH, Georgas E, Arndt C, Otto T. Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy Anticancer Drugs. 2013 Apr;24(4):422-5

18. Gerullis H, Klosterhalfen B, Borós M, Lammers B, Eimer C, Georgas E, Otto T. IDEAL in meshes for prolapse, urinary incontinence and hernia repair. Surg Innov. 2013 Oct;20(5):502-8

17. Gerullis H, Eimer C, Georgas E, Homburger M, El-Baz AG, Wishahi M, Borós M, Ecke TH, Otto T. Muscle-derived cells for treatment of iatrogenic sphincter damage and urinary incontinence in men. ScientificWorldJournal. 2012;2012:898535.

16. Ecke TH, Hallmann S, Koch S, Ruttloff J, Cammann H, Gerullis H, Miller K, Stephan C. External validation of an artificial neural network and two normograms for prostate cancer detection. ISRN Urol. 2012;2012:643181

15. Selinski S, Lehmann ML, Blaszkewicz M, Ovsiannikov D, Moormann O, Guballa C, Kress A, Truss MC, Gerullis H, Otto T, Barski D, Niegisch G, Albers P, Frees S, Brenner W, Thüroff JW, Angeli-Greaves M, Seidel T, Roth G, Volkert F, Ebbinghaus R, Prager HM, Bolt HM, Falkenstein M, Zimmermann A, Klein T, Reckwitz T, Roemer HC, Hartel M, Weistenhöfer W, Schöps W, Rizvi SA, Aslam M, Bánfi G, Romics I, Ickstadt K, Hengstler JG, Golka K. Rs11892031>A@ on chromosome 2q37 in an intronic region oft he UGT1A locus is associated with urinary bladder cancer risk. Arch Toxicol. 2012 Sep;86(9):1369-78

14. Gerullis H, Georgas E, Eimer C, Goretzki PE, Lammers BJ, Klosterhalfen B, Boros M,Wishahi M, Heusch G, Otto T. Evaluation of Biocompatibility of Alloplastic Materials: Development of a Tissue Culture In Vitro Test System. Surg Technol Int. 2011 Dec;21:21-7

13. Gerullis H, Georgas E, Quast S, Eimer C, Homburger M, Orzechowski D, Altindag M, Rübben H, Otto T. Early endoscopic detection and subsequent removal of sphincter penetrating anastomotic sutures may prevent irreversible urinary incontinence after radical prostatectomy. J Endourol. 2012 Jul;26(7):889-94

12. Gerullis H, Eimer C, Ecke TH, Georgas E, Freitas C, Kastenholz S, Arndt C, Heusch C, Otto T. A phase II trial of temsirolimus in second-line metastatic urothelial cancer. Med Oncol. 2012 Dec;29(4):2870-6

11. Selinski S, Lehmann ML, Blaszkewicz M, Ovsiannikov D, Moormann O, Guballa C, Kress A, Truss MC, Gerullis H, Otto T, Barski D, Niegisch G, Albers P, Frees S, Brenner W, Thüroff JW, Angeli-Greaves M, Seidel T, Roth G, Volkert F, Ebbinghaus R, Prager HM, Lukas C, Bolt HM, Falkenstein M, Zimmermann A, Klein T, Reckwitz T, Roemer HC, Hartel M, Weistenhöfer W, Schöps W, Rizvi SA, Aslam M, Bánfi G, Romics I, Ickstadt K, Hengstler JG, Golka K. Urinary bladder cancer risk in relation to a single nucleotide polymorphism (rs2854744) in the insulin-like growth factor-binding protein-3 (IGFBP3) gene. Arch Toxicol. 2012 Feb;86(2):195-203

10. AJ, Verhaegh GW, Hulsbergen-van de Kaa CA, Gerullis H, et al. European genome-wide association study identifies SLC14A1 as new urinary bladder cancer susceptibility gene. Hum Mol Genet. 2011 Nov 1;20(21):4268-81

9. Gerullis H, Quast S, Eimer C, Bagner JW, Otto T. Sphincter lesions after radical prostatectomy-evaluation and classification. J Endourol. 2011 Jun;25(6):1075-80

8. Lehmann ML, Selinski S, Blaszkewicz M, Orlich M, Ovsiannikov D, Moormann O, Guballa C, Kress A, Truss MC, Gerullis H, Otto T, Barski D, Niegisch G, Albers P, Frees S, Brenner W, Thüroff JW, Angeli-Greaves M, Seidel T, Roth G, Dietrich H, Ebbinghaus R, Prager HM, Bolt HM, Falkenstein M, Zimmermann A, Klein T, Reckwitz T, Roemer HC, Löhlein D, Weistenhöfer W, Schöps W, Beg AE, Aslam M, Bánfi G, Romics I, Ickstadt K, Schwender H, Winterpacht A, Hengstler JG, Golka K. Rs710521[A] on chromosome 3q28 close to TP63 is associated with increased urinary bladder cancer risk. Arch Toxicol. 2010 Dec;84(12):967-78

7. Ecke TH, Gerullis H, Heuck CJ, Bartel P, Hallmann S, Koch S, Ruttloff J. Does a new ultrasound probe change the complication rates of transrectal ultrasound-guided needle biopsies oft he prostate? Anticancer Res. 2010 Jul;30(7):3071-6

6. Gerullis H, Ecke TH, Schwartmann K, Heuck CJ, Eimer C, Bagner JW, Kocheril S, Otto T. Nephrocutaneous bypass in ureteral obstruction. Urology. 2010 Aug;76(2):4805

5. Ecke TD, Gerullis H, Bartel P, Koch S, Ruttloff J. Gemcitabine, paclitaxel, and cisplatin as combined adjuvant approach in transitional cell carcinoma of the urothelium. Minerva Urol Nefrol. 2009 Sep;61(3):249-56

4. Ecke TH, Gerullis H, Bartel P, Koch S, Ruttloff J. Palliative chemotherapy with gemcitabine, paclitaxel, and cisplatin as first-line treatment following gemcitabine monotherapy for patients with transitional cell carcinoma oft he urothelium. Minerva Urol Nefrol. 2009 Mar;61(1):1-8

3. Gerullis H, Bergmann L, Maute L, Ecke TH, Eimer C, Bagner JW, Otto T. Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma. Med Oncol. 2010 Jun;27(2):373-8

2. Gerullis H, Bergmann L, Maute L, Eimer C, Otto T. Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany. Cancer Chemother Pharmacol. 2009 May;63(6):1097-102

1. Gerullis H, Kuemmel C, Popken G. Laparoscopic cystectomy with extracorporeal-assisted urinary diversion: experience with 34 patients. Eur Urol. 2007 Jan;51(1):193-8

Reviews, Case reports, Letters in Journals

30. Barski D, Gerullis H, Ecke T, Varga G, Boros M, Pintelon I, Timmermans JP, Otto T. Human amniotic membrane dressing for the treatment of an
infected wound due to an entero-cutaneous fistula: Case report. Int J Surg Case Rep. 2018;51:11-13.

29. Selinski S, Blaszkewicz M, Ickstadt K, Gerullis H, Otto T, Roth E, Volkert F, Ovsiannikov D, Moormann O, Banfi G, Nyirady P, Vermeulen SH, Garcia-
Closas M, Figueroa JD, Johnson A, Karagas MR, Kogevinas M, Malats N, Schwenn M, Silverman DT, Koutros S, Rothman N, Kiemeney LA, Hengstler JG, Golka K. Identification and replication of the interplay of four genetic high-risk variants for urinary bladder cancer. Carcinogenesis. 2017 Dec 7;38(12):1167-1179.

28. Selinski S, Gerullis H, Otto T, Roth E, Volkert F, Ovsiannikov D, Salem J, Moormann O, Geis BC, Niedner H, Blaszkewicz M, Hengstler JG, Golka K. Ultra-slow N-Acetyltransferase 2 Is Associated with recurrence-free Time in Bladder Cancer Patients. Eur Urol. 2017 Jun;71(6):994-995

27. Gerullis H, Eitzen A, Uphoff J, Daaboul F, Chavan A, Ermert L, Wawroschek F, Winter A. Recurrent symphysitis culminating in pelvic ring fracture after hyperextended transurethral prostate resection and vaporization with symphysis erosion: a case report. J Med Case Rep. 2017 May 19;11(1):141

26. Barski D, Gerullis H, Otto T. Review of surgical implant procedures for male incontinence after radical prostatectomy according to IDEAL framework. Updates Surg. 2017 May 6. doi: 10.1007/s13304-017-0460-x. [Epub ahead of print]

25. Gerullis H, Barski D, Malmström PU, Sun X, Ecke TH. Evidence in Urologic- and Pelvic-Surgery Research: Finding the IDEAL Way of Reporting. Biomed Res Int. 2017;2017:2716759

24. Winter A, Engels S, Kowald T, Paulo TS, Gerullis H, Chavan A, Wawroschek F. Magnetic Sentinel Lymph Node Detection in Prostate Cancer after intraprostatic Injection of Supermagnetic Iron Oxide Nanoparticels. Aktuelle Urol. 2017 Apr;48(2):132-139

23. Gerullis H, Wawroschek F, Köhne CH, Ecke TH. Vinflunine in the treatment of advanced urothelial cancer: clinical evidence and experience. Ther Adv Urol. 2017 Jan;9(1):28-35

22. Barski D, Georgas E, Gerullis H, Ecke T. Metastatic penile carcinoma – an update on the current diagnosis and treatment options. Cent European J Urol 2014;67(2):126-32

21. Barski D, Otto T, Gerullis H. Systematic review and classification of comlications after anterior, posterior, apical and total vaginal mesh implantation for prolapse repair. Surg Technol Int. 2014 Mar;24:217-24

20. Gerullis H, Georgas E, Bagner JW, Eimer C, Otto T. Construction of a penoid after penectomy using a transpositioned testicle. Urol Int. 2013;90(2):240-2

19. Gerullis H, Otto T, Ecke TH. Targeted agents in second-line bladder cancer therapy. Anticancer Drugs. 2012 Nov;23(10):1003-15

18. Golka K, Abreu-Villaca Y, Anbari Attar R, Angeli-Greaves M, Aslam M, Basaran N, Belik R, Butryee C, Dalpiaz O, Dzhusupov K, Ecke TH, Galambos H, Galambos H, Gerilovica H, Gerullis H, Gonzalez PC, Goossens ME, Gorgishvili-Hermes L, Heyns CF, Hodzic J, Ikoma F, Jichlinski P, Kang BH, Kiesswetter E, Krishnamurthi K, Lehmann ML, Martinova I, Mittal RD, Ravichandran B, Romics I, Roy B, Rungkat-Zakaria F, Rydzynski K, Scutaru C, Shen J, Soufi M, Toguzbaeva K, Vu Duc T, Widera A, Wishahi M, Hengstler JG. Bladder cancer documentation of causes: multilingual questionnaire, `bladder cancer doc. Front Biosci (Elite Ed). 2012 Jun 1;4:2709-22

17. Gerullis H, Ecke TH, Janusch B, Arndt C, Heidari M, Oniani J, Otto T. Long-term response in advanced bladder cancer involving the use of temsirolimus and vinflunine after platin resistance. Anticancer Drugs. 2011 Oct;22(9):940-3

16. Gerullis H. Vinflunine: a flourinated vinca alkaloid for bladder cancer therapy. Drugs Today (Barc). 2011 Jan;47(1):17-25

15. Gerullis H, Ecke TH, Wishahi M, Georgas E, Eimer C, Otto T. What happens if nothing happens? History of an untreated urothelial carcinoma of the bladder. J Egypt Soc Parasitol. 2010 Dec;40(3):789-96.

14. Ecke TH, Gerullis H, Heuck CJ, Hallmann S, Lange C, Ruttloff J. Idiopathic giant abdominal lymph cyst: a case report. J Med Case Rep. 2011 Jan 19;5:21

13. Eimer C, Gerullis H, Heuck C, Otto T. mTOR inhibition in advanced renal cell carcinoma: which criteria should be used to evaluate therapeutic outcome? Anticancer Drugs. 2011 Jan;22(1):18-23

12. Gerullis H, Ecke T, Eimer C, Wishahi M, Otto T. Vinflunine as second-line treatment in platin resistant metatsatic urothelial carcinoma: a review. Anticancer Drugs. 2011 Jan;22(1):9-17

11. Gerullis H, Ecke TH, Eimer C, Heuck CJ, Otto T. mTOR-inhibition in metastatic renal cell carcinoma. Focus on temsirolimus: a review. Minerva Urol Nefrol. 2010 Dec;62(4):411-23

10. Gerullis H, Heuck CJ, Schneider P. Breast pseudotumoral radionecrosis as a late radiation-induced injury: a case report. J Med Case Rep. 2009 Oct 8;3:71

9. Ecke TH, Hallmann S, Gerullis H, Ruttloff J. Reconstruction of the urethra with Surgisis onlay patch in urethral reconstructive surgery: two case reports. J Med Case Rep. 2009 Mar 16;3:7232

8. Otto T, Gerullis H, Theuerkauf I. Re: White et al.: Comparative analysis of surgical margins between radical retropubic prostatectomy and RALP: Are patients sacrificed during initiation of robotic program? (Urology 2009;73:567-571) Urology. 2009 Aug;74(2):475-6

7. Otto T, Eimer C, Gerullis H. Temsirolimus in renal cell carcinoma. Transplant Proc. 2008 Dec;40(10 Suppl):S36-9

6. Gerullis H, Eimer C, Betz D, Otto T. Successful transureteropyelostomy after heminephrectomy of a bilateral hydronephrotic horseshoe kidney: a case report. J Med Case Rep. 2008 Jul 16;2:231

5. Otto T, Theuerkauf I, Tscheuschner S, Janusch B, Gerullis H. Targeted therapy in uro-oncology. Deutsche Zeitschrift für Onkologie 2009, 41 (1), pp. 10-14

4. Otto T, Gerullis H, Musch A. Temsirolimus - mTOR als neue Zielstruktur in der Therapie des fortgeschrittenen Nierenzellkarzinoms. AMT, Arzneimitteltherapie, 26. Jahrgang Heft 8, August 2008, 275-283

3. Eimer C, Gerullis H, Otto T. Targeted therapy des metastasierten Nierenzellkarzinoms (mRCC). Onkopipeline, 2008;1:82–90

2. Otto T, Bagner JW, Eimer C, Gerullis H, Ramon A. Wiederherstellung des Blasenschließmuskels mit körpereigenen Muskelzellen zur Kontinenz. Uro-News 2008, (11) 24-28

1. Gerullis H, Otto T. Vinflunin (Javlor). Second-Line-Therapie bei metastasiertem Urothelkarzinom nach Versagen platinhaltiger First-Line-Therapie. Internistische Praxis, 2012 Jahrgang 52 Heft 3, S. 629

Buchbeiträge

21. Otto T, Eimer C, Gerullis H. Standards in der Nierentumorbehandlung. In: Otto T (Hrsg.): mTOR-Inhibition - Ein neuer Wirkmechanismus in der Onkologie, 1. Auflage, Bremen: UNI-MED, 2009: 40-51, ISBN 978-3-8374-2019-7

20. Gerullis H, Eimer C, Maute L, Bergmann L. Erfahrungen aus dem Temsirolimus Compassionate Use-Programm. In: Otto T (Hrsg.): mTOR-Inhibition - Ein neuer Wirkmechanismus in der Onkologie, 1. Auflage, Bremen: UNI-MED, 2009: 66-73, ISBN 9783-8374-2019-7

19. Eimer C, Wishahi M, Kretschmar T, Gerullis H. Lebensqualität. In: Otto T (Hrsg.): mTOR-Inhibitoren – Update 2011, 2. Auflage, Bremen: UNI-MED, 2011: 116-123, ISBN 978-3-8374-2158-3

18. Otto T, Gerullis H, Gibbons J, Schmidinger M. mTOR-Inhibitoren in Forschung und Praxis.In: Otto T (Hrsg.): mTOR-Inhibitoren – Update 2013, 3. Auflage, Bremen: UNIMED, 2013:13-22, ISBN 978-3-8374-2158-3

17. Gerullis H, Niegisch G. mTOR-Inhibition beim Urothelkarzinom.In: Otto T (Hrsg.): mTOR-Inhibitoren – Update 2013, 3. Auflage, Bremen: UNI-MED, 2013: 111-114, ISBN 978-3-8374-2158-3

16. Gerullis H, Winter A. IDEAL – Ausweg aus dem Dilemma? In: Otto T, Lammers BJ, Schumpelick V (Hrsg.): Implantate in der Chirurgie – Update 2015. UNI-MED, Bremen. 1. Auflage 2015: 103-6. ISBN-10: 383741454X

15. Barski D, Bagner JW, Gerullis H, Otto T. Alloplastische Netze und ihre operative Entfernung bei Komplikationen. In: Hoffmann R, Wagner U (Hrsg.): Inkontinenz- und Deszensuschirurgie der Frau. 2. Auflage, Springer Verlag 2015: 219-229, ISBN 978-3-66243671-4

14. Bremer J, Schenck M, Gerullis H, Otto T. Nierenzellkarzinom. In: Rübben H, Otto T (Hrsg.): Colloquium Urologie 2010, 1. Auflage, München: Agileum Verlag und Gesundheitsakademie GmbH, 2010: 73-104, ISBN 978-3-939415-08-4

13. Otto T, Becker M, Börgermann C, Bremer J, vom Dorp F, Eimer C, Gerullis H, Hess J, Jäger T, Janusch B, Pelzer N, Peschkes C, Quast S, Schenck M, Tschirdewahn S. Uroloonkologie. In: Rübben H, Otto T (Hrsg.): Colloquium Urologie 2011, 2. Auflage, München: Agileum Verlag und Gesundheitsakademie GmbH, 2011: 5-131, ISBN 9783-939415-11-4

12. Otto T, Gerullis H, Eimer C, Hess J, Pelzer N, Börgermann C. Prostatakarzinom. In: Rübben H, Otto T (Hrsg.): Colloquium Urologie 2012, 2. Auflage, München: Agileum Verlag und Gesundheitsakademie GmbH, 2012: 89-142, ISBN 978-3-939415-14-5

11. Otto T, Gerullis H, Eimer C, Tschirdewahn S, vom Dorp F, Becker M. Harnblasenkarzinom. In: Rübben H, Otto T (Hrsg.): Colloquium Urologie 2012, 2. Auflage, München: Agileum Verlag und Gesundheitsakademie GmbH, 2012: 143-172, ISBN 978-3939415-14-5

10. Otto T, Gerullis H, Eimer C, Bremer J, Schenck M. Nierenzellkarzinom. In: Rübben H,

9. Otto T (Hrsg.): Colloquium Urologie 2012, 2. Auflage, München: Agileum Verlag und Gesundheitsakademie GmbH, 2012: 173-194, ISBN 978-3-939415-14-5

8. Otto T, Gerullis H, Eimer C, vom Dorp F. Tumoren des männlichen Genitale. In: Rübben H, Otto T (Hrsg.): Colloquium Urologie 2012, 2. Auflage, München: Agileum Verlag und Gesundheitsakademie GmbH, 2012: 195-202, ISBN 978-3-939415-14-5

7. Otto T, Gerullis H, Eimer C. Seltene Tumoren. In: Rübben H, Otto T (Hrsg.): Colloquium Urologie 2012, 2. Auflage, München: Agileum Verlag und Gesundheitsakademie GmbH, 2012: 203-208, ISBN 978-3-939415-14-5

6. Bremer J, Schenck M, Gerullis H, Eimer C, Otto T. Nierenzellkarzinom. In: Rübben H, Otto T (Hrsg.): Colloquium Urologie 2013, 2. Auflage, München: Agileum Verlag und Gesundheitsakademie GmbH, 2013: 141-166, ISBN 978-3-939415-17-6

5. Vom Dorp F, Eimer C, Gerullis H, Otto T. Tumoren des männlichen Genitale. In: Rübben H, Otto T (Hrsg.): Colloquium Urologie 2013, 2. Auflage, München: Agileum Verlag und Gesundheitsakademie GmbH, 2013: 167-176, ISBN 978-3-939415-17-6

4. Barski D, Gerullis H. Implantate in der Urogynäkologie – Quo vadis. In: Rübben H, Otto T (Hrsg.): Colloquium Urologie 2015, 2. Auflage, München: Agileum Verlag und Gesundheitsakademie GmbH, 2015:17-30, ISBN 978-3-939415-24-4

3. Barski D, Gerullis H. Plädoyer für ein Register in der Implantatmedizin. In: Rübben H, Otto T (Hrsg.): Colloquium Urologie 2016, 2. Auflage, München: Agileum Verlag und Gesundheitsakademie GmbH, 2016: 39-46, ISBN 978-3-939415-27-5

2. Otto T, Yang J, Gerullis H, Hubens G. Harnblasenkarzinom. In: Rübben H, Otto T (Hrsg.): Colloquium Urologie 2016, 2. Auflage, München: Agileum Verlag und Gesundheitsakademie GmbH, 2016: 86-100, ISBN 978-3-939415-27-5

1. Otto T, Schenck M, Gerullis H, Ramon A, Timmermans JP, Ponsaerts P. Nierenzellkarzinom. In: Otto T, Steffens JA, Rübben H (Hrsg.): Colloquium Urologie 2017, 2. Auflage, München: Agileum Verlag und Gesundheitsakademie GmbH, 2017: 25-46,

ISBN 978-3-939415-39-5

Ausgewählte zitierfähige Abstracts

Niegisch G, Gerullis H, Lin SW, Pavlova J, Gondos A, Rudolph A, Haas G, Hennies N, Kramer MW. Real-world survival outcomes in patients with advanced urothelial cancer in Germany. Ann Oncol 2017; 28 (Suppl 5) 1117p

Gerullis H, Ecke TH, Bantel C, Weyland A, Barski D, Jansen T, Uphoff J, Wawroschek F, Winter A. Radical cystectomy in epidural anaesthesia – Feasibility analysis using a new reporting method following the IDEAL recommendations. Int J Surg 2016; 36 (Suppl 2):137.

Barski D, Gerullis H, Winter A, Pintelon I, Timmermans JP, Ramon A, Boros M, Varga G, Otto T. Reconstruction of bladder defects with amniotic membrane - IDEAL-D Stage 0-1. Int J Surg 2016; 36 (Suppl 2):136.

Gerullis H, Barski D, Ecke TH, Eimer C, Boros M, Klosterhalfen B, Ramon A, Otto T. Autologous plasma coating improves biocompatibility of mesh implants. On the IDEAL way from bench to bedside. Int J Surg 2016; 36 (Suppl 2):142

Ecke TH, Weingart G, Lange C, Hallmann S, Wawroschek F, Barski D, Ruttloff J, Gerullis H. Percutaneous nephrolithotomy (PCNL) under local infiltrative anesthesia with and without stand-by anesthesia – Complication rates and clinical outcome for a method at the exploration stage according to IDEAL. Int J Surg 2016; 36 (Suppl 2):142

Barski D, Gerullis H, Ecke T, Joukhadar R, Kranz J, Tahbaz R, Queissert F, Schneidewind L, Mühlstädt S, Grabbert M, Huppertz N, Pelzer AE, Klinge U, Boros M, Bader W, Puppe W, Otto T. Development of an online platform for registration and outcome measurement of urogynecological implants according to IDEAL-system. Int J Surg 2016; 36 (Suppl 2):141-142

Winter A, Kowald T, Paulo T, Goos Ph, Engels S, Gerullis H, Chavan A, Wawroschek F. Magnetic resonance sentinel lymph node imaging in prostate cancer using intraprostatic injection of superparamagnetic iron oxide nanoparticles: The first in-human results. Urologe A 2016; 55 (Suppl 1):47.

Winter A, Engels S, Goos Ph, Süykers MC, Gudenkauf S, Henke RP, Gerullis H, Wawroschek F. Magnetometer guided sentinel lymphadenectomy after intraprostatic injection of superparamagnetic iron oxide nanoparticles in intermediate and high risk prostate cancer patients. Urologe A 2016; 55 (Suppl 1):72.

Winter A, Engels S, Goos Ph, Süykers MC, Gudenkauf S, Henke RP, Gerullis H, Barski D, Wawroschek F. Magnetometer guided sentinel lymphadenectomy after intraprostatic injection of super-paramagnetic iron oxide nanoparticles in intermediare and high risk prostate cancer patients. J Urol 2016; 195 (4, Suppl):e987.

Winter A, Kowald T, Paulo TS, Goos Ph, Engels S, Gerullis H, Chavan A, Wawroschek F. Magnetic resonance sentinel lymph node imaging in prostate cancer using intraprostatic injection of superparamagnetic iron oxide nanoparticles: The first in-human results. Eur Urol Suppl 2016; 15(3):1060.

Barski D, Gerullis H, Winter A, Pintelon I, Timmermans JP, Ramon A, Boros M, Varga G, Otto. Augmentation of rat bladder with human amniotic membrane graft. Eur Urol Suppl 2016; 15(3):e1027.

Höhne, S, Gerullis H, Blaszkewicz M, Selinski S, Niedner H, Hengstler JG, Golka K, Otto T. Einfluss des N-Acetyltransferase 1*10 Genotyps auf das Harnblasenkarzinomerkrankungsrisiko. 62. Kongress der Nordrhein-Westfälischen Gesellschaft für Urologie: meeting abstracts, Münster, 14.-15.04.2016 (S. DocP3.6). Düsseldorf: German Medical Science GMS Publishing House, 2016.

Selinski S, Geis B, Gerullis H, Otto T, Niedner H, Blaszkewicz M, Hengstler JG, Golka K. Ultra-slow N-acetyltransferase 2 (NAT2) and prognosis in bladder cancer patients Naunyn-Schmiedeberg's Arch. Pharmacol. 389 (Suppl 1): S57 (2016)

Winter A, Engels S, Goos P, Süykers MC, Gudenkauf S, Henke RP, Gerullis H, Wawroschek F. Magnetometer guided sentinel lymphadenectomy after intraprostatic injection of superparamagnetic iron oxide nanoparticles in intermediate- and high-risk prostate cancer patients. J Urol Suppl. (2016), Vol 195, Issue 4, e987

Winter A, Kowald T, Paulo T, Goos P, Engels S, Gerullis H, Chavan A, Wawroschek F. Magnetic resonance sentinel lymph node imaging in prostate cancer using intraprostatic injection of supermagnetic iron oxide nanoparticles: The first in-human results. Eur Urol Suppl (2016) Vol.15, Issue 3, e1060

Ecke T, Arndt C, Gützlaff S, Stephan C, Lux O, Otto T, Hallmann S, Ruttloff J, Gerullis H. Detection of carcinoma in situ (CIS) of urinary bladder cancer using UBC® Rapid as tumour marker. Eur Urol Suppl. (2016), Vol.15, Issue 3, e750

Barski D, Gerullis H, Winter A, Pintelon I, Timmermans J-P, Ramon A, Boros M, Varga G, Otto T. Augmentation of rat bladder with human amniotic membrane graft. Eur Urol Suppl. (2016) Vol.15, Issue 3, e1027

Ecke TH, Arndt C, Lux O, Otto T, Hallmann S, Ruttloff J, Gerullis H. New Results of a Multicentre-study for UBC rapid as Marker for Urinary Bladder Cancer. Tumor Biol 2015; 36 (Suppl 1): S56

Gerullis H, Georgas E, Barski D, Boros M, Klosterhalfen B, Lammers B, Eimer C, Ramon A, OttoT. A novel approach for assessment and improvement of surgical meshes. Hernia 2014, Vol 18, Suppl 2 , P171

Gerullis H, Boros M, Klosterhalfen B, Heusch G, Georgas E, Eimer C, Otto T. Improving bioperformance of meshes for SUI and POP by coating with autologous plasma – results of a long term aninmal study. Eur Urol Suppl. (2013) Vol. 12, Issue 1, e251

Gerullis H, Eimer C, Georgas E, Bagner JW, Otto T. Temsirolimus in platinum-resistant metastatic urothelial cancer: A phase II trial. J Clin Oncol 30, no.5 suppl (2012) 302-302

Gerullis H, Eimer C, Georgas E, Otto T. Temsirolimus in Second-Line Metastatic Urothelial Cancer – A Phase II Trial. Eur Urol Suppl. (2012), Vol. 11, Issue 4, p117

Gerullis H, Eimer C, Georgas E, Lammers B, Goretzki P, Klosterhalfen B, Boros M, Ramon A, Otto T. Improved biocompatibility of meshes used for hernia, incontinence and organ prolapse repair by plasma coating – results of in vitro and in vivo studies.

Eur Urol Suppl. (2012), Vol. 11, Issue 1, e1068

Gerullis H, Georgas E, Eimer C, Lammers B, Goretzki P, Klosterhalfen B, Boros M, Ramon A, Otto T. Evaluation of biocompatibility of alloplastic materials – development of a tissue culture in vitro test system. Eur Urol Suppl. (2012), Vol. 11, Issue 1, e807

Gerullis H, Eimer C, Ramon A, Wishahi M, Heusch G, Klosterhafen B, Boros M, Bagner J, Otto T. Improved Biocompatibility of Meshes used for Hernia, Incontinence and Organ Prolapse Repair by Plasma Coating – Results of in in vitro an din vivo Studies. J Urol Suppl. (2011) Vol. 185, Issue 4, e317

Eimer C, Quast S, Gerullis H, Otto T. Prevention of Urinary Stress Incontinence Caused by Radical Retropubic Prostatectomy (RRP) by Early Endoscopic Removal oft he Anastomosis Sutures. J Urol Suppl. (2010), Vol 183, Issue 4, e618

Eimer C, Gerullis H, Karig R, Goretzki P, Otto T. Therapy of Refractory Postoperative

Urinary Stress Incontinence by the Use of Autologous Skeletal Muscle-Derived Cells (MDC). J Urol Suppl. (2010), Vol 183, Issue 4, e587

Gerullis H, Eimer C, Karig R, Goretzki P, Ramon A, Otto T. Therapy of Refractory Postoperative Stress Urinary Incontinence by the Use of Autologous Skeletal MuscleDerived Cells (MDC). Eur Urol Suppl. (2010), Vol. 9, Issue 2, p329

Eimer C, Gerullis H, Bagner J, Lammers BJ, Theuerkauf, I Ramon A, Otto T. In Vitro Test System for the Evaluation of the Biocompatibility of Alloplastic Materials. Eur Urol Suppl. (2010) Vol. 9, Issue 2, p109

Eimer C, Quast S, Gerullis H, Otto T. Evaluation and Classification of Sphincter Lesions due to Radical Prostatectomy (RP). Eur Urol Suppl. (2010) Vol. 9, Issue 2, p105

Eimer C, Quast S, Gerullis H, Otto T. Prevention of Urinary Stress Incontinence Caused by Radical Reropubic Prostatectomy (RRP) by Early Endoscopic Removal oft he Anastomosis Sutures. J Urol Suppl. (2010) Vol. 183, Issue 4, e618

Eimer C, Gerullis H, Karig R, Goretzki P, Ramon A, Otto T. Therapy of Refractory Postoperative Stress Incontinence by the Use of Autologous Skeletal Muscle-Derived

Cells (MDC). J Urol Suppl. (2010), Vol. 183, Issue 4, e587

Bagner J, Gerullis H, Karig R, Ramon A, Otto T. In vitro test system fort he evaluation oft he biocompatibility of alloplastic materials and ist improvement by autologous coating. Urology Suppl (2010),Vol.76, Issue 3, S21–S22

Karig R, Bagner J, Gerullis H, Eimer C, Ramon A, Otto T. Treatment of refractory postoperative urinary stress incontinence by the use of autologous satellite cells (SLC). Urology Suppl (2010),Vol.76, Issue 3, S1

Karig R, Bagner J, Gerullis H, Eimer C, Quast S, Otto T. evaluation and classification of sphincter lesions due to radical prostatectomy (RP). Urology Suppl (2010),Vol.76, Issue 3, S77

Gerullis H, Bergmann L, Maute L, Bagner J, Eimer C, Otto T. Experiences and Practical Conclusions Concerning Temsirolimus USe and Adverse Event Management in Advanced Renal Cell Carcinoma Within a Compassionate USe Program in Germany. Urology Suppl (2009),Vol.74, Issue 4, S261

Gerullis H, Bergmann L, Maute L, Ecke T, Eimer C, Bagner J, Otto T. Feasibility of Sequential Use of Sunitinib and Temsirolimus in Advanced Renal Cell Carcinoma. Urology Suppl (2009),Vol.74, Issue 4, S261

Gerullis H, Eimer C, Bagner J, Tscheuschner S, Otto T. Repair of Iatrogenic Sphincter

Damage and Urinary Incontinence by Autologous Skeletal Muscle Derived Cells (MDC). Urology Suppl (2009),Vol.74, Issue 4, S2

Gerullis H, Eimer C, Bagner J, Otto T. In Vitro Test Pattern for Determination of Biocompatibility of Alloplastic Materials Used for Treatment of Urinary Incontinence. Urology Suppl (2009),Vol.74, Issue 4, S232

Gerullis H, Tscheuschner S, Eimer C, Bagner J, Otto T. Radical Prostatectomy and Sphincter Damage. What Can We Learn from the Pitfalls. Urology Suppl (2009),Vol.74, Issue 4, S2

Otto T, Eimer C, Gerullis H. Sphincter Repair with autologous Skeletal Muscle Derived Cells (MDC) – What do we transplant? Eur Urol Suppl. (2008) Vol. 7, Issue 3, p317 Otto T, Eimer C, Gerullis H. Repair of iatrogenic Sphincter Damage and Urinary Incontinence by autologous Skeletal Muscle Derived Cells (MDC). Eur Urol Suppl. (2008) Vol. 7, Issue 3, p87

Otto T, Eimer C, Gerullis H. Repair of Iatrogenic Sphincter Damage and Urinary Incontinence by Autologous Skeletal Muscle Derived Cells (MDC). J Urol Suppl. (2008), Vol 179, Issue 4, p 484

Otto T, Eimer C, Gerullis H. Experience with the German „Compassionate Use Program“ (CUP) for Temsirolimus (TEMSR) in Patients with Advanced Renal Cell Carcinoma (RCC). Eur Urol Suppl (2008) Vol. 7, Issue 3, p308

Otto T, Tscheuschner S, Eimer C, Gerullis H, Schwartmann K, Bagner J. Radical Prostatectomy (RP) and Sphincter Damage – What can we learn from the Pitfalls? Eur Urol Suppl. (2008) Vol. 7, Issue 3, p88

Otto T, Eimer C, Bagner J, Gerullis H, Schwartmann K, Bornemeyer K. Tissue engineering with autologous unipotent Skeletal Muscle Cells in external Sphincter Insufficiency III. Eur Urol Suppl. (2007) Vol. 6, Issue 2, p73

Ausgewählte Vorträge auf wissenschaftlichen Kongressen

Selinski S, Gerullis H, Otto T, Roth E, Volkert F, Ovsiannikov D, Salem J, Moormann O, Geis BC, Blaszkewicz M, Hengstler JG, Golka K. Ultra-langsamer N-Acetyltransferase 2 (NAT”) Genotyp und rezidiv-freies Überleben von Harnblasenkrebspatienten. 11. Nordkongress Urologie, Rostock-Warnemünde. 2017, 15.-17.6.2017, HF 10.1

Barski D, Puppe F, Klinge U, Joukhadar R, Gerullis H, Otto T. German register of urogynecological implants – first results. Annual Meeting of the International urogynecological association (IUGA), Nizza, 2016, Abstract 176

Gerullis H, Ecke T, Bantel C, Weyland A, Barski D, Uphoff J, Winter A, Wawroschek F. Radikale Zystektomie in epiduralerAnästhesie – Machbarkeitsuntersuchung unter Anwendung einer neuen Darstellungsmethode nach IDEAL Empfehlung. Nordkongress Urologie, Berlin. 2016, 16.-18.6.

Winter A, Kowald T, Paulo TS, Goos Ph, Engels S, Gerullis H, Chavan A, Wawroschek F. Magnetic resonance sentinel lymph node imaging in prostate cancer using intraprostatic injection of superparamagnetic iron oxide nanoparticles. ISNS Biannual Meeting, Mailand. 2016, 30.04.-02.05.

Wawroschek F, Winter A. Oldenburg Experience. Consensus Meeting Sentinel Node Procedure in Prostate Cancer, Berlin. 2016, 25.-26.02.

Gerullis H, Ecke T, Bantel C, Weyland A, Barski D, Uphoff J, Winter A, Wawroschek F. Radikale Zystektomie in epiduraler Anästhesie – Machbarkeitsuntersuchng unter Anwendung einer neuen Darstellungsmethode nach den IDEAL Kriterien. 10. Nordkongress Urologie, Berlin 2016, HF7.10

Ecke TH, Arndt C, Gützlaff S, Lux O, Stephan C, Otto T, Hallmann S, Gerullis H. Results of a multicenter-study for UBC® Rapid as marker for urinary bladder cancer with focus on high risk tumours. Vortrag, Suomen Urologiyhdistyksen Talvipäivät 2016, Turku, Finnland, 12.02.2016

Selinski S, Geis BC, Gerullis H, Otto T, Roth E, Volkert F, Ovsiannikov D, Salem J, Moormann O, Niedner H, Blaszkewicz M, Hengstler JG, Golka K. Ultra-slow N-acetyltransferase 2 (NAT2) and relapse-free time in bladder cancer patients. In: Deutscher Forschungsverbund Blasenkarzinom e. V.: Symposium des Deutschen Forschungsverbundes Blasenkarzinom e. V.. Düsseldorf, 19./20.02.2016. Programm und Abstracts (S. 15). Düsseldorf, 2016

Höhne S, Gerullis H, Blaszkewicz M, Selinski S, Niedner H, Hengstler JG, Otto T, Golka K. N-Acetyltransferase 1*10 Genotyp und Harnblasenkarzinom. In: DGAUM, Deutsche Gesellschaft für Arbeitsmedizin und Umweltmedizin e.V. (Hrsg.): 56. Wissenschaftliche Jahrestagung 2016 “Ressourcen und Stressoren in der Arbeitswelt. Molekulare Arbeitsmedizin. Betriebliches Gesundheitsmanagement”. Programm und Abstracts der Vorträge und Poster, München, 09.-11. März 2016 (S 106). Stuttgart: Gentner Verlag, 2016

Gerullis, H, Barski D, Boros M, Klosterhalfen B, Ramon A, Eimer C, Otto T. Coating von Meshes mit autologem Plasma. Auf dem IDEALen Weg von Bench to Bedside. 10. Nordkongress Urologie, Berlin 2016, HF7.10

Barski D, Gerullis H, Ecke T, Klinge U, Boros M, Bader W, Puppe F, Otto T. Register der urogynäkologischen Implantate: Entwicklung einer Online-Plattform entsprechend der IDEAL Prüfungsmethode der chirurgischen Innovationen. Forum Urodynamikum,

Rostock 2016, Abstract 17

Barski D, Gerullis H, Otto T. Systematischer Vergleich der Komplikationen nach der vaginalen Deszensuskorrektur im vorderen Kompartiment mit nativem Gewebe und Netzen. 61. Jahrestagung der Nordrhein-Westffälischen Gesellschaft für Urologie,

NRWGU 2015, Köln, P 1.24

Winter A, Sirri E, Jansen L, Kieschke J, Gondos A, Holleczek B, Emrich K, Waldmann A, Brenner H for the GEKID Cancer Survival Group. Entwicklung des relativen 5- und 10-Jahresüberleben und der Stadienverteilung beim Prostatakarzinom in der PSA-Ära: Ein populationsbezogener Vergleich zwischen Deutschland und den USA. 67. Kongress der Deutschen Gesellschaft für Urologie e.V., Hamburg. 2015, 23.-26.09.

Höhne S, Gerullis H, Blaszkewicz M, Selinski S, Hengstler J, Otto T, Golka K. NAcetyltransferase 1*10 genotype in bladder cancer patients. Environmental Toxicology in North Rhine-Westphalia, Germany – Interdisciplinary research activities in toxicology, statistic, hygiene and medicine. Scientific symposium, Dortmund, May 7-8, 2015. Abstracts (p 60). Dortmund: IfADo, 2015

Höhne S, Gerullis H, Blaszkewicz M, Selinski S, Niedner H, Hengstler JG, Golka K, Otto T. Einfluss des N-Acetyltransferase 1*10 Genotyps auf das Harnblasenkarzinomerkrankungsrisiko. 62. Jahrestagung der Nordrhein-Westffälischen Gesellschaft für Urologie, NRWGU 2015, Münster, P 3.6

Ecke TH, Arndt C, Lux O, Otto T, Hallmann S, Ruttloff J, Gerullis H. New results of a multicenter-study for urinary bladder cancer antigen (UBC) rapid as marker for urinary bladder cancer. Poster, ESUR-SBUR15, 11th World Congress Meeting on Urological Research, Nijmegen, Niederlande, 11.09.2015

Ecke TH, Arndt C, Lux O, Otto T, Hallmann S, Ruttloff J, Gerullis H. New Results of a Multicentre-Study for UBC rapid as Marker for Urinary Bladder Cancer. Poster, 42.

Congress of the ISOBM, Zakopane, Poland, 04.10.2015

Barski D, Gerullis H, Georgas E, Klosterhalfen B, Borors M, Otto T. Coating of Mesh graftsfor prolapse and urinary incontinence repair with autologous plasma: 1-year results. Annual Meeting of the International urogynecological association (IUGA), Nizza, 2015, Abstract 316

Barski D, Georgas E, Gerullis H, Heidari M, Quast S, Karig R, Bagner JW, Otto W, Otto T. Der Ileumpouch – Eine neue Form der Harnableitung. 60. Jahrestagung der Nordrhein-Westffälischen Gesellschaft für Urologie, NRWGU 2014, Düsseldorf, V 2.4

Gerullis H, Georgas E, Barski D, Boros M, Klosterhalfen B, Lammers B, Eimer E, Ramon A, OttoT. A novel approach for assessment and improvement of surgical meshes. 36th international congress oft he European Hernia Society, Edinburgh, Scotland, Hernia 2014, Vol 18, Suppl 2, P171

Barski D, Gerullis H, Otto T. Systematic review and classification of complications after anterior, posterior, apical and combined vaginal mesh implantation for prolapse repair. International Continence Society Annual Meeting 2014, Rio de Janeiro, Abstract 362

Barski D, Gerullis H, Georgas E, Boros M, Klosterhalfen B, Lammers B, Otto T. Modification of mesh materials for prolapse and urinary incontinence repair by autologous plasma coating: a feasibility trial. International Continence Society Annual Meeting 2014, Rio de Janeiro, Abstract 432

Barski D, Joukhadar R, Solomeyer E, Klinge U, Puppe F, Gerullis H, Otto T. Register of urogynecological implants – a german initiation trial. International Continence Society Annual Meeting 2014, Rio de Janeiro, Abstract 475

Barski D, Gerullis H, Georgas E, Steven D, Schwartmann K, Otto T. Nephrokutaner Bypass bei Ureterobstruktion. 60. Jahrestagung der Nordrhein-Westffälischen Gesellschaft für Urologie, NRWGU 2014, Düsseldorf, P 2.52

Barski D, Georgas E, Gerullis H, Karig R, Bagner JW, Quast S, Otto T. Prospektive

Untersuchung zum Einfluss multiperforierter Katheter bei der radikalen retropubischen Prostatovesikulektomie (RRP). 60. Jahrestagung der Nordrhein-Westffälischen Gesellschaft für Urologie, NRWGU 2014, Düsseldorf, V 5.5

Gerullis H, Eimer C., Georgas E., Barski D., Otto T. Kombinationstherapie mit Vinflunine und Pazopanib beim fortgeschrittenen Urothelkarzinom nach Platinversagen Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie 2013, Wien, V415